Vanguard Group
BIO icon

Vanguard Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Vanguard Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$538M Sell
1,774,263
-19,274
-1% -$6.01M 0.01% 1015
2025
Q3 		$503M Sell
1,793,537
-53,006
-3% -$14.4M 0.01% 1066
2025
Q2 		$446M Sell
1,846,543
-65,614
-3% -$15.5M 0.01% 1094
2025
Q1 		$466M Sell
1,912,157
-7,651
-0.4% -$2.3M 0.01% 1034
2024
Q4 		$631M Buy
1,919,808
+12,168
+0.6% +$4.13M 0.01% 902
2024
Q3 		$638M Sell
1,907,640
-466,867
-20% -$148M 0.01% 893
2024
Q2 		$649M Sell
2,374,507
-46,827
-2% -$13.6M 0.01% 831
2024
Q1 		$837M Buy
2,421,334
+31,445
+1% +$10.3M 0.02% 724
2023
Q4 		$772M Buy
2,389,889
+46,119
+2% +$14.5M 0.02% 733
2023
Q3 		$840M Sell
2,343,770
-51,443
-2% -$19.8M 0.02% 650
2023
Q2 		$908M Sell
2,395,213
-2,113
-0.1% -$860K 0.02% 648
2023
Q1 		$1.15B Buy
2,397,326
+5,890
+0.2% +$2.76M 0.03% 554
2022
Q4 		$1.01B Buy
2,391,436
+39,908
+2% +$16.1M 0.03% 579
2022
Q3 		$981M Buy
2,351,528
+2,428
+0.1% +$1.21M 0.03% 570
2022
Q2 		$1.16B Buy
2,349,100
+31,159
+1% +$16.2M 0.03% 525
2022
Q1 		$1.31B Buy
2,317,941
+30,476
+1% +$18.4M 0.03% 549
2021
Q4 		$1.73B Buy
2,287,465
+18,200
+0.8% +$13.6M 0.04% 479
2021
Q3 		$1.69B Sell
2,269,265
-12,433
-0.5% -$9.31M 0.04% 471
2021
Q2 		$1.47B Sell
2,281,698
-6,440
-0.3% -$3.92M 0.04% 515
2021
Q1 		$1.31B Buy
2,288,138
+15,765
+0.7% +$9.34M 0.04% 531
2020
Q4 		$1.32B Buy
2,272,373
+19,165
+0.9% +$10.9M 0.04% 491
2020
Q3 		$1.16B Sell
2,253,208
-52,973
-2% -$26.8M 0.04% 477
2020
Q2 		$1.04B Buy
2,306,181
+292,900
+15% +$129M 0.04% 484
2020
Q1 		$706M Buy
2,013,281
+35,754
+2% +$13.1M 0.03% 539
2019
Q4 		$732M Buy
1,977,527
+54,278
+3% +$19.1M 0.03% 662
2019
Q3 		$640M Buy
1,923,249
+19,938
+1% +$6.5M 0.02% 682
2019
Q2 		$595M Sell
1,903,311
-11,937
-0.6% -$3.57M 0.02% 724
2019
Q1 		$585M Buy
1,915,248
+29,183
+2% +$7.88M 0.02% 719
2018
Q4 		$438M Buy
1,886,065
+53,097
+3% +$14.2M 0.02% 765
2018
Q3 		$574M Buy
1,832,968
+35,261
+2% +$10.9M 0.02% 722
2018
Q2 		$519M Buy
1,797,707
+42,741
+2% +$11.8M 0.02% 755
2018
Q1 		$439M Buy
1,754,966
+31,854
+2% +$8.11M 0.02% 815
2017
Q4 		$411M Buy
1,723,112
+29,116
+2% +$7.06M 0.02% 845
2017
Q3 		$376M Buy
1,693,996
+14,591
+0.9% +$3.28M 0.02% 862
2017
Q2 		$380M Buy
1,679,405
+6,131
+0.4% +$1.34M 0.02% 831
2017
Q1 		$334M Buy
1,673,274
+58,774
+4% +$11.3M 0.02% 878
2016
Q4 		$294M Buy
1,614,500
+64,149
+4% +$10.9M 0.02% 925
2016
Q3 		$254M Buy
1,550,351
+52,157
+3% +$7.92M 0.01% 958
2016
Q2 		$214M Buy
1,498,194
+63,322
+4% +$9.03M 0.01% 1015
2016
Q1 		$196M Buy
1,434,872
+47,403
+3% +$6.22M 0.01% 1041
2015
Q4 		$192M Buy
1,387,469
+40,044
+3% +$5.55M 0.01% 1038
2015
Q3 		$181M Buy
1,347,425
+7,115
+0.5% +$1.02M 0.01% 1050
2015
Q2 		$202M Buy
1,340,310
+43,543
+3% +$6.23M 0.01% 1052
2015
Q1 		$175M Buy
1,296,767
+86,378
+7% +$10.7M 0.01% 1112
2014
Q4 		$146M Buy
1,210,389
+21,850
+2% +$2.51M 0.01% 1157
2014
Q3 		$135M Buy
1,188,539
+16,719
+1% +$1.98M 0.01% 1163
2014
Q2 		$140M Buy
1,171,820
+24,811
+2% +$3.03M 0.01% 1177
2014
Q1 		$147M Buy
1,147,009
+58,091
+5% +$7.45M 0.01% 1104
2013
Q4 		$135M Buy
1,088,918
+46,522
+4% +$5.67M 0.01% 1129
2013
Q3 		$123M Buy
1,042,396
+24,885
+2% +$2.93M 0.01% 1108
2013
Q2 		$114M Buy
+1,017,511
New +$119M 0.01% 1078

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Vanguard Group's BIO Position: Q4 2025 in Review

Vanguard Group reduced its Bio-Rad Laboratories Class A (BIO) stake by 1.1% in Q4 2025, selling an estimated $6.01M and leaving 1,774,263 shares worth $538M. The position accounts for 0.01% of the portfolio, ranked #1015.

Vanguard Group first reported a position in BIO in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.73B in Q4 2021. 396 funds tracked by Wall St. Rank hold BIO as of Q4 2025.

  • Vanguard Group held 1,774,263 shares of Bio-Rad Laboratories Class A worth $538M as of Q4 2025.
  • Vanguard Group sold 19,274 Bio-Rad Laboratories Class A shares in Q4 2025, an estimated $6.01M.
  • Bio-Rad Laboratories Class A made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1015 holding.
  • Vanguard Group first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Bio-Rad Laboratories Class A position peaked at $1.73B in Q4 2021.
  • 396 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.